Abcellera Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Abcellera Biologics
ABCL Stock  USD 4.92  0.23  4.47%   
Abcellera Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Abcellera Biologics' valuation are provided below:
Gross Profit
-147.4 M
Market Capitalization
1.5 B
Enterprise Value Revenue
40.2841
Revenue
23.1 M
Earnings Share
(0.56)
There are over one hundred nineteen available fundamental signals for Abcellera Biologics, which can be analyzed over time and compared to other ratios. We recommend to validate Abcellera Biologics' prevailing fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 819.3 M. The Enterprise Value is projected to slide to about 732.8 M

Abcellera Biologics Total Revenue

27.39 Million

Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 40.4 M, Interest Income of 40.4 M or Depreciation And Amortization of 101.8 M, as well as many indicators such as Price To Sales Ratio of 28.41, Dividend Yield of 0.0 or PTB Ratio of 0.78. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
  
Build AI portfolio with Abcellera Stock
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Abcellera Biologics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.4 B499.5 M
Slightly volatile
Short and Long Term Debt Total43.7 M65.4 M21.8 M
Slightly volatile
Other Current Liabilities49.5 M37.1 M22.8 M
Slightly volatile
Total Current Liabilities86.8 M76.6 M43.2 M
Slightly volatile
Total Stockholder Equity836 M1.1 B390.5 M
Slightly volatile
Other Liabilities69.6 M129.5 M40.5 M
Slightly volatile
Net Tangible Assets1.3 B1.2 B384.1 M
Slightly volatile
Property Plant And Equipment Net357.5 M340.4 M87.4 M
Slightly volatile
Current Deferred Revenue11.6 M13.5 M6.5 M
Slightly volatile
Accounts Payable18.4 M34.4 M9.2 M
Slightly volatile
Cash277.3 M156.3 M132.8 M
Slightly volatile
Non Current Assets Total367.5 M609.2 M172.3 M
Slightly volatile
Long Term Debt1.6 M2.5 M1.4 M
Slightly volatile
Cash And Short Term Investments566.9 M625.6 M266.1 M
Slightly volatile
Net Receivables90 M92.1 M42.1 M
Slightly volatile
Common Stock Total Equity479 M844.5 M267.2 M
Slightly volatile
Common Stock Shares Outstanding281.5 M294.3 M205.1 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.4 B499.5 M
Slightly volatile
Non Current Liabilities Total139.3 M227.9 M65.8 M
Slightly volatile
Inventory1.1 M1.3 M514.6 K
Slightly volatile
Other Current Assets32.6 M33.6 M15.3 M
Slightly volatile
Other Stockholder Equity472.1 M449.7 M73.4 M
Slightly volatile
Total Liabilities226.1 M304.5 M109 M
Slightly volatile
Net Invested Capital835.1 M1.1 B388.1 M
Slightly volatile
Property Plant And Equipment Gross399.2 M380.1 M96.1 M
Slightly volatile
Short and Long Term Debt162.4 K171 K1.6 M
Slightly volatile
Total Current Assets694.5 M751.4 M327.2 M
Slightly volatile
Capital Stock585 M777.2 M275.6 M
Slightly volatile
Non Current Liabilities Other1.4 M1.5 M9.9 M
Pretty Stable
Net Working Capital607.7 M674.8 M284.1 M
Slightly volatile
Short Term Debt4.1 M4.6 M3.2 M
Slightly volatile
Common Stock582.6 M777.2 M270.7 M
Slightly volatile
Property Plant Equipment262.3 M249.8 M71.4 M
Slightly volatile
Non Currrent Assets Other101.4 M96.5 M23.9 M
Slightly volatile
Other Assets102 M97.1 M26.9 M
Slightly volatile
Good Will49 M55 M37.1 M
Slightly volatile
Short Term Investments536.2 M469.3 M557.2 M
Slightly volatile
Long Term Investments63.9 M82.3 M34.2 M
Slightly volatile
Intangible Assets40 M42.1 M109.3 M
Slightly volatile
Retained Earnings Total Equity381.6 M490.1 M308.5 M
Slightly volatile
Capital Surpluse60.2 M85.2 M44.9 M
Slightly volatile
Deferred Long Term Liabilities28.2 M29.9 M35.8 M
Slightly volatile

Abcellera Biologics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income40.4 M38.5 M8.8 M
Slightly volatile
Depreciation And Amortization101.8 M97 M17.5 M
Slightly volatile
Interest Expense2.5 M4.7 M1.5 M
Slightly volatile
Selling General Administrative76.3 M72.7 M18.9 M
Slightly volatile
Selling And Marketing Expenses7.1 M12.8 M3.6 M
Slightly volatile
Total Revenue27.4 M28.8 M57.2 M
Slightly volatile
Other Operating Expenses360.8 M343.6 M87.9 M
Slightly volatile
Research Development87.7 M167.3 M43.3 M
Slightly volatile
Cost Of Revenue101.8 M97 M26.9 M
Slightly volatile
Total Operating Expenses360.8 M343.6 M82.1 M
Slightly volatile
Reconciled Depreciation101.8 M97 M18.5 M
Slightly volatile
Total Other Income Expense Net120.1 M114.4 M21 M
Slightly volatile
Non Recurring61.6 M76.4 M51.1 M
Slightly volatile
Non Operating Income Net Other20.5 M26 M16.8 M
Slightly volatile

Abcellera Biologics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation34.9 M67.6 M16.3 M
Slightly volatile
Depreciation101.8 M97 M18.5 M
Slightly volatile
Capital Expenditures48.9 M78.4 M25.1 M
Slightly volatile
End Period Cash Flow294.2 M183.6 M140.6 M
Slightly volatile
Change To Netincome67.5 M64.3 M18.5 M
Slightly volatile
Dividends Paid11.3 K12.7 K13.9 K
Slightly volatile
Cash Flows Other Operating117.5 M176 M83 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio28.4129.9095626
Slightly volatile
PTB Ratio0.780.8166488
Slightly volatile
Days Sales Outstanding1.2 K1.2 K257
Slightly volatile
Book Value Per Share2.153.58811.3506
Slightly volatile
Stock Based Compensation To Revenue2.462.34390.4634
Slightly volatile
Capex To Depreciation0.770.80824.1655
Slightly volatile
PB Ratio0.780.8166488
Slightly volatile
EV To Sales25.4226.7547625
Slightly volatile
Inventory Turnover39.5632.0950.6158
Slightly volatile
Days Of Inventory On Hand9.5511.778.3742
Slightly volatile
Payables Turnover3.972.82383.7372
Pretty Stable
Sales General And Administrative To Revenue2.652.52180.5926
Slightly volatile
Research And Ddevelopement To Revenue6.095.8011.4881
Slightly volatile
Capex To Revenue2.852.7190.858
Slightly volatile
Cash Per Share1.462.12560.9265
Slightly volatile
Days Payables Outstanding101129109
Slightly volatile
Intangibles To Total Assets0.130.06610.1362
Slightly volatile
Current Ratio5.189.80754.3349
Slightly volatile
Tangible Book Value Per Share1.843.28261.1579
Slightly volatile
Receivables Turnover0.30.3134.9543
Slightly volatile
Shareholders Equity Per Share2.153.58811.3506
Slightly volatile
Debt To Equity0.05880.06190.2274
Slightly volatile
Capex Per Share0.280.26640.1049
Slightly volatile
Average Receivables1.4 M1.6 M1.7 M
Slightly volatile
Revenue Per Share0.09310.0980.3033
Slightly volatile
Interest Debt Per Share0.120.22210.0859
Slightly volatile
Debt To Assets0.04560.0480.123
Slightly volatile
Graham Number3.956.622.7317
Slightly volatile
Short Term Coverage Ratios11310744.4863
Slightly volatile
Operating Cycle1.2 K1.2 K261
Slightly volatile
Price Book Value Ratio0.780.8166488
Slightly volatile
Days Of Payables Outstanding101129109
Slightly volatile
Company Equity Multiplier1.651.28831.683
Slightly volatile
Long Term Debt To Capitalization0.00290.0030.0493
Slightly volatile
Total Debt To Capitalization0.05540.05830.1713
Slightly volatile
Debt Equity Ratio0.05880.06190.2274
Slightly volatile
Quick Ratio5.179.80754.3298
Slightly volatile
Net Income Per E B T0.890.81270.9754
Slightly volatile
Cash Ratio2.942.04052.1639
Slightly volatile
Days Of Inventory Outstanding9.5511.778.3742
Slightly volatile
Days Of Sales Outstanding1.2 K1.2 K257
Slightly volatile
Price To Book Ratio0.780.8166488
Slightly volatile
Fixed Asset Turnover0.08050.08472.0517
Very volatile
Debt Ratio0.04560.0480.123
Slightly volatile
Price Sales Ratio28.4129.9095626
Slightly volatile
Asset Turnover0.02010.02120.3182
Slightly volatile
Price Fair Value0.780.8166488
Slightly volatile

Abcellera Biologics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap819.3 M862.4 M7 B
Slightly volatile
Enterprise Value732.8 M771.4 M6.9 B
Slightly volatile

Abcellera Fundamental Market Drivers

Forward Price Earnings27.4725
Cash And Short Term Investments625.6 M

Abcellera Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Abcellera Biologics Financial Statements

Abcellera Biologics investors utilize fundamental indicators, such as revenue or net income, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue13.5 M11.6 M
Total Revenue28.8 M27.4 M
Cost Of Revenue97 M101.8 M
Stock Based Compensation To Revenue 2.34  2.46 
Sales General And Administrative To Revenue 2.52  2.65 
Research And Ddevelopement To Revenue 5.80  6.09 
Capex To Revenue 2.72  2.85 
Revenue Per Share 0.10  0.09 
Ebit Per Revenue(10.92)(10.37)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:
How To Invest In Abcellera
Details
Is Abcellera Stock a good investment?
Details
What is Abcellera Biologics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.459
Earnings Share
(0.56)
Revenue Per Share
0.078
Quarterly Revenue Growth
(0.57)
Return On Assets
(0.13)
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY